Sutro Biopharma, Inc. financial data

Symbol
STRO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
111 Oyster Point Blvd., South San Francisco, CA
Fiscal year end
December 31
Former names
Fundamental Applied Biology Inc (to 10/24/2007)
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 374 % -31.2%
Debt-to-equity 255 % +72.2%
Return On Equity -97 % +5.82%
Return On Assets -27.3 % +34.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 82.5M shares +35.3%
Common Stock, Shares, Outstanding 82.4M shares +35.3%
Entity Public Float 278M USD +11%
Common Stock, Value, Issued 82K USD +34.4%
Weighted Average Number of Shares Outstanding, Basic 82M shares +35.4%
Weighted Average Number of Shares Outstanding, Diluted 82M shares +35.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 161M USD +231%
Research and Development Expense 235M USD +38.3%
General and Administrative Expense 56.2M USD -7.06%
Operating Income (Loss) -130M USD +28.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -108M USD +36.4%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -124M USD +28.1%
Earnings Per Share, Basic -1.61 USD/shares +44.3%
Earnings Per Share, Diluted -1.61 USD/shares +44.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 175M USD +113%
Marketable Securities, Current 214M USD -10.7%
Accounts Receivable, after Allowance for Credit Loss, Current 6.66M USD -60%
Assets, Current 406M USD +6.43%
Property, Plant and Equipment, Net 19M USD -15%
Operating Lease, Right-of-Use Asset 19M USD -20.7%
Other Assets, Noncurrent 7.17M USD +119%
Assets 452M USD +4.66%
Accounts Payable, Current 6.22M USD +12.5%
Accrued Liabilities, Current 13.2M USD +15.9%
Contract with Customer, Liability, Current 72.6M USD +203%
Liabilities, Current 131M USD +78.4%
Contract with Customer, Liability, Noncurrent 18M USD -77%
Operating Lease, Liability, Noncurrent 17.7M USD -29%
Other Liabilities, Noncurrent 1.69M USD
Liabilities 341M USD +6.65%
Accumulated Other Comprehensive Income (Loss), Net of Tax 106K USD +1414%
Retained Earnings (Accumulated Deficit) -714M USD -21%
Stockholders' Equity Attributable to Parent 111M USD -1.08%
Liabilities and Equity 452M USD +4.66%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -64.7M USD -6.15%
Net Cash Provided by (Used in) Financing Activities -3.43M USD -139%
Net Cash Provided by (Used in) Investing Activities 64.1M USD -4.96%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 82.4M shares +35.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.07M USD -127%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 175M USD +112%
Interest Paid, Excluding Capitalized Interest, Operating Activities 63K USD -84%
Deferred Tax Assets, Valuation Allowance 168M USD +27.8%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 181M USD +27%
Operating Lease, Liability 24.9M USD -19.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -124M USD +27.6%
Lessee, Operating Lease, Liability, to be Paid 29.2M USD -23.9%
Property, Plant and Equipment, Gross 64.1M USD +2.52%
Operating Lease, Liability, Current 7.2M USD +16.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.99M USD -5.65%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.53M USD +3.41%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.3M USD -40.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.29M USD -7.84%
Deferred Tax Assets, Operating Loss Carryforwards 37.2M USD -38.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 8.73M USD +0.94%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.29M USD -7.84%
Operating Lease, Payments 2.3M USD +35.3%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.76M USD +9.04%
Deferred Tax Assets, Net of Valuation Allowance 13.1M USD +17.3%
Share-based Payment Arrangement, Expense 25M USD +1.87%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%